Skip to main content
Log in

The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria

  • Published:
Journal of Inherited Metabolic Disease

Summary

Maternal phenylketonuria (PKU) represents a high risk for birth defects, including mental retardation, in offspring. Thus, it could cancel gains represented by the prevention of PKU-induced mental retardation in the current generation. Effective dietary treatment of maternal PKU pregnancies could avoid this potentially tragic occurrence. However, dietary compliance is often difficult because a necessary component of the diet, medical nutritional formulas, often have an unpleasant taste and odour. We treated the second pregnancy of a phenylketonuric women who had required extended hospitalization during her first pregnancy because of poor formula tolerance, and who had similar difficulty in the second pregnancy. To alleviate this problem, we developed a system whereby she could pack the formula into gelatin capsules for ingestion. Packing and ingestion of 20 capsules required less than 30 minutes three times a day. With capsules her blood phenylalanine level was almost always within the recommended range of 120–360 µmol/L (2–6 mg/dl) and hospitalization was not required. The phenylalanine content of the capsules was easily accommodated by a small reduction in allowable food. Other amino acid levels, including tyrosine and other essential nutrient levels, were normal. We believe that using gelatin capsules for formula ingestion can be very beneficial in the management of maternal PKU pregnancies and could be extended to the dietary treatment of other inborn errors of metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Drogari E, Beasley M, Smith I, Lloyd JK (1987) Timing of strict diet in relation to fetal damage in maternal phenylketonuria.Lancet 2: 927–930.

    Google Scholar 

  • Hogan SE, Gates RD, MacDonald GW, Clarke JTR (1986) Experience with adolescents with phenylketonuria returned to phenylalanine-restricted diets.J Am Diet Assoc 86: 1203–1207.

    Google Scholar 

  • Kirkman HN (1982) Projections of a rebound in frequency of mental retardation from phenylketonuria.Appl Res Ment Retard 3: 319–328.

    Google Scholar 

  • Koch R, Hanley W, Levy H et al (1990) A preliminary report of the Collaborative Study of Maternal Phenylketonuria in the United States and Canada.J Inher Metab Dis 13: 641–650.

    Google Scholar 

  • Lenke RR, Levy HL (1980) Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of untreated and treated pregnancies.N Engl J Med 303: 1201–1208.

    Google Scholar 

  • Lenke RR, Levy HL (1982) Maternal phenylketonuria — results of dietary therapy.Am J Obstet Gynecol 141: 548–553.

    Google Scholar 

  • Levy HL (1991) Nutritional therapy in inborn errors of metabolism. In Desnick RJ, ed.Treatment of Genetic Diseases. New York: Churchill Livingstone, pp. 1–22.

    Google Scholar 

  • Schuett VE, Brown E, Michals K (1985) Reinstitution of diet therapy in PKU patients from 22 U.S. clinics.Am J Publ Health 75: 39–42.

    Google Scholar 

  • Schuett VE, Gurda RF, Brown ES (1980) Diet discontinuation policies and practices of PKU clinics in the United States.Am J Publ Health 70: 498–503.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kecskemethy, H.H., Lobbregt, D. & Levy, H.L. The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria. J Inherit Metab Dis 16, 111–118 (1993). https://doi.org/10.1007/BF00711324

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00711324

Keywords

Navigation